mild to moderate chronic dermatitis. Dermatitis, unspecified
Conditions
Interventions
Intervention 1: Intervention group: Intervention group: Recipient of Portulaca oleracea syrup (25 mg/ ml) 10 cc three times a day for 4 weeks orally prepared to contain aqueous extract of Portulaca ol
Sponsors
Shahid Beheshti University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: Patients with chronic unilateral or bilateral hand dermatitis, including occupational dermatitis, allergic dermatitis or irritative dermatitis Age range 18 to 70 years Willingness and satisfaction to participate in the study Referred to traditional medicine center
Exclusion criteria
Exclusion criteria: Breastfeeding Pregnancy Patients with severe dermatitis Patients with underlying diseases such as cardiovascular failure, diabetes, immune deficiency, autoimmune diseases, spinal cord diseases Patients taking medication for their other illnesses Patients who develop another acute illness during treatment Patients who have an infection at the site of their dermatitis Patients who are allergic to Portulaca oleracea
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Erythema. Timepoint: Week zero, the end of the fourth and eighth weeks. Method of measurement: HECSI Scale.;Edema. Timepoint: Week zero, the end of the fourth and eighth weeks. Method of measurement: HECSI Scale.;Fissure. Timepoint: Week zero, the end of the fourth and eighth weeks. Method of measurement: HECSI Scale.;Scaling. Timepoint: Week zero, the end of the fourth and eighth weeks. Method of measurement: HECSI Scale.;Itching. Timepoint: Week zero, the end of the second, fourth and eighth weeks. Method of measurement: VAS Scale.;Dryness. Timepoint: Week zero, the end of the second, fourth and eighth weeks. Method of measurement: VAS Scale.;Skin thickness. Timepoint: Week zero, the end of the second, fourth and eighth weeks. Method of measurement: VAS Scale.;Drug side effects. Timepoint: Week zero, the end of the second, fourth and eighth weeks. Method of measurement: Question from the patient. | — |
Secondary
| Measure | Time frame |
|---|---|
| Dermatology life quality index. Timepoint: Week zero, the end of the fourth and eighth weeks. Method of measurement: DLQI questionnair.;Patients' overall satisfaction with treatment. Timepoint: End of the fourth week. Method of measurement: Likert Scale.;Recurrence of symptoms after treatment. Timepoint: the end of the eighth week. Method of measurement: Question from the patient. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactSedigheh Rastegar
Shahid Beheshti University of Medical Sciences
Outcome results
None listed